Doug Drysdale On How CYB-003 Is Better Than Psilocybin

In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.

The conversation then pivots to what Cybin sees as the main issues with psilocybin: its long duration of effect, long period before onset action, and the variability in effects from person to person.